

# EU-LAC HEALTH "2<sup>nd</sup> ROADMAPPING WORKSHOP" February 26-27, 2014 – Madrid, Spain

### THE STRATEGIC ACTION PLAN AND ROADMAP

# Joaquín Guinea, INNOVATEC



EU-CELAC JOINT INITIATIVE ON HEALTH RESEARCH STRATEGIC ACTION PLAN



### EU-CELAC JOINT INITIATIVE ON HEALTH RESEARCH STRATEGIC ACTION PLAN (DRAFT)

#### INDEX

#### EXECUTIVE SUMMARY

- 1. BACKGROUND
- 2. CURRENT CONTEXT AND CHALLENGES AHEAD
- 3. VISION AND MISION
  - 3.1 Benefits of the Research coordination
  - 3.2 Vision
  - 3.3 Mission

#### 4 SWOT Analysis

- 5. SCIENTIFIC RESEARCH AGENDA
  - 5.1<sub>c.t.</sub> Research Priority Setting for International Cooperation between EU and LAC in the Health area.
  - 5.2. Core research themes included in the scientific research agenda
    - 5.2.1: Health and social care services research
    - 5.2.2: Infection
    - 5.2.3 Neurological diseases and stroke
    - 5.2.4: Chronic diseases
    - . 5.2.1: Prevention of diseases and promotion of well-being
    - 5.2.6: Cancer
- 6. EU- CELAC- JOINT INITIATIVE ON HEALTH RESEARCH GOVERNANCE
  - 6.1 Introduction
  - 6.2 Proposed Governance and management structures for the EU-CELAC- Joint Initiative on Health Research
- 7. STRATEGIC ROADMAP 2015-2020

#### ANNEXES:

- ANNEX 1: MEMBERS OF THE EULAC HEALTH SCIENTIFIC WORKING GROUPS
- ANNEX 2: COLLABORATIVE HEALTH RESEARCH PROJECTS FUNDED BY FP7
- ANNEX 3: MAIN MESSAGES FROM THE 2nd LATIN AMERICAN CONFERENCE ON RESEARCH AND INNOVATION FOR HEALTH
- ANNEX 4: HEALTH RELATED SOCIETAL CHALLENGES EXPECTED TO BE ADDRESSED IN THE HORIZON 2020 PROGRAMME
- ANNEX 5: INTERNATIONAL PARTICIPATION IN HORIZON 2020
- ANNEX 6: GLOSSARY
- ANNEX 7: REFERENCE DOCUMENTS



**DRAFT February 2014** 





## • THE OBJECTIVE OF THIS DOCUMENT IS:

TO PRESENT THE EU-CELAC JOINT INITIATIVE ON HEALTH
RESEARCH (EU-CELAC JIHR) PROPOSAL, PREPARED BY THE EULAC HEALTH PROJECT, FOR ITS VALIDATION BY STAKEHOLDERS
THROUGH A CONSULTATION PROCESS



#### 1. BACKGROUND



- Long history in the partnership between the European Union (EU) and the Latin America and the Caribbean (LAC) countries
- Since the Rio de Janeiro Summit in 1999, the EU-LAC dialogue on Science and Technology (S&T) has been present and continuous efforts have been undertaken to define and implement joint S&T programmes
- During the Madrid Declaration (May 2010), the EU-LAC JOINT INITIATIVE FOR RESEARCH AND INNOVATION (JIRI) between the EU and the Community of Latin America and Caribbean States (CELAC) was approved
- In April 2013, the Senior Official Meeting (SOM) that prepares and implements this JIRI approved the creation of a Working Group on Health Research
- The EU-LAC Health project will provide technical background and concrete thematic proposals to this Working Group on Health Research



#### 2. CURRENT CONTEXT AND CHALLENGES AHEAD

- <u>Health research</u> stands as one of the major areas of R&D expenditure in both regions, all together represented around 40,000 million euros in 2010\*:
  - > 18% of the total Gross Domestic Expenditure on R&D (GERD) in EU-27
  - > 9.5% of the total GERD in LAC
  - > Around 30% of the total scientific publication in EU-27 and around 25% in LAC are in the health area
  - ➤ 85 bilateral S&T cooperation agreement and cooperation programmes which work as regular funding instruments aiming at supporting activities between the EU and LAC countries, 25 specifically address the Health area
  - ➤ The EU Seventh Framework Programme (FP7), has funded 37 health research projects with a total budget of around 150 million Euros, involving around 500 research groups of both regions in a variety of topics ranging from infectious diseases, cancer and chronic diseases to health systems or evaluation of health policies
- The <u>Joint Initiative for Research and Innovation</u> (JIRI) has changed the working scenario for policy decision making in research cooperation between EU and CELAC Regions:
  - > The ALCUE-NET project
  - ➤ The ERANET-LAC

<sup>\*</sup> Rottingen J-A, Regmi S, Fide M, et al. (2013). Wapping of available health research and development data: what's under grant agreement n° 281459. there, what's there, what's missing, and what role is there for a global observatory? Lancet; published online May 20.

#### 3. VISION AND MISION



THE EU-CELAC JIHR will build a sustainable collaborative health research effort between policy makers, researchers and stakeholders from Europe and Latin America and the Caribbean that results in better interventions to improve the health and economic and social wellbeing of citizens



#### 3. VISION AND MISION



### BENEFITS OF THE RESEARCH COORDINATION

- Facilitate addressing common challenges together, developing common solutions and speaking with one voice
- Promote scientific excellence
- Reach expertise scattered across several countries
- Enable rapid dissemination of research results
- Increase the scientific, technological and innovative impacts
- Have a positive impact on both regions populations



#### 3. VISION AND MISION



#### **EU-CELAC JOINT INITIATIVE ON HEALTH RESEARCH OBJECTIVES**

- To address common challenges, aligning research programmes and avoiding unwanted duplications
- To maximize synergies among national partners putting together expertise scattered across different countries
- To increase the scientific and societal impact of the research
- To increase the overall value for money of the public expenditures in health research

#### THE KEY PRINCIPLES OF THE EU-CELAC JOINT INITIATIVE ON HEALTH RESEARCH

- Jointly defined strategic research agenda tackling global challenges
- Improved integration of national/regional activities through existing or novel innovative funding schemes.
- Co-responsibility, co-ownership and inclusiveness
- Flexibility to allow reacting to the changing landscape
- Sound operational strategy
- Transparency, accountability and visibility of the initiative





#### 4. SWOT ANALYSIS OF THE EU-CELAC JOINT INITIATIVE ON HEALTH RESEARCH

THE WILL			
STRENGTHS	WEAKNESSESS		
<ul> <li>Alignment with present political scenario of the EU CELAC S/T collaboration.</li> </ul>	Requires difficult long-term political support.      Risk of creating inoffective bureaucrasy.		
<ul> <li>It is able to take advantage of existing health research resources in the countries as starting point.</li> <li>Can avoid unwanted duplication of research.</li> <li>Facilitates sustainability in science and technology cooperation on a long term basis.</li> <li>Enable to attract external funds (ie. from developmental aid agencies for low income countries).</li> </ul>	<ul> <li>Risk of creating ineffective bureaucracy.</li> <li>Fragmentation of the EU and LAC research due to the variety of agencies and organizations supporting Health research in the LAC and EU regions.</li> <li>"Size effect" and disparity between resources and capacities.</li> <li>Different approaches to R&amp;D priority setting and funding schemes.</li> <li>Overcoming legal obstacles including IPR &amp; technology transfer arrangements.</li> </ul>		
<ul> <li>High visibility and high potential impact.</li> </ul>	<i>5,</i> 5		
OPPORTUNITIES	THREATS		
<ul> <li>Good instrument to implement the SOM Health research group recommendations.</li> <li>Better opportunities in capacities, innovation and infrastructure collaboration.</li> </ul>	<ul> <li>Risk of failure due to geopolitics and other issues.</li> <li>Discontinuation of commitment in national research planning&amp;funding.</li> <li>Difficult negotiation when differing national agendas.</li> </ul>		
<ul> <li>Attractive for participation of external parties and funding.</li> </ul>	<ul> <li>Creation of other bi/multiregional Health research initiatives seeking similar objectives.</li> </ul>		
<ul> <li>Reference initiative for health research cooperation         -LAC HEALTH has received funding from the European Union `s Seventh         between Europe and LAC countries.         der grant agreement if 281459.</li> </ul>	Framework Programme (FP7/2007-2013)		

#### 5. SCIENTIFIC RESEARCH AGENDA



- > RESEARCH PRIORITY SETTING FOR INTERNATIONAL COOPERATION
  BETWEEN EU AND LAC IN THE HEALTH AREA
- CORE RESEARCH THEMES INCLUDED IN THE SCIENTIFIC RESEARCH AGENDA
  - Health and social care services research
  - Infection
  - Neurological diseases and stroke
  - Chronic diseases
  - Prevention of diseases and promotion of well-being
  - Cancer





# 6. EU- CELAC- JOINT INITIATIVE ON HEALTH RESEARCH GOVERNANCE

PROPOSED GOVERNANCE AND MANAGEMENT STRUCTURES FOR THE EU-CELAC- JOINT INITIATIVE ON HEALTH RESEARCH

#### **EU- CELAC- JOINT INITIATIVE ON HEALTH RESEARCH**

#### **GOVERNING BOARD**

Representatives from EU-CELAC health research funding agencies and supranational institutions

Chair and Vice-Chairs

SCIENTIFIC SECRE ADVISORY BOARD

Working group

Working group

Working group

Working group

Working group

#### **SECRETARIAT**

(Management unit)

STAKEHOLDER ADVISORY BOARD





# 7. PRELIMINARY STRATEGIC ROADMAP OF THE EU-CELAC JOINT INITIATIVE ON HEALTH RESEARCH (2014-2020) - 1

	EU-LAC Health	ACTIVITIES			MILESTONES (expected by
EU-CELAC JIHR CALENDAR	Project life **	POLICY GOVERNANCE	SCIENTIFIC GUIDANCE	STAKEHOLDERS' INVOLVEMENT	the end of each period)
2014		Interact with the SOM health group to develop and discuss the EU-CELAC JIHR and its Strategic Action Plan      Meeting with SOM group to present the Strategic Action Plan	Draft Scientific     Agenda.	Strengthen coordination with related initiatives (H2020, PAHO, CYTED, Cooperation agencies, GACD, IRDIRC etc.)	STRATEGIC ACTION PLAN (INCLUDING STRATEGIC RESEARCH AGENDA) VALIDATED BY SOM
1st. semester 2015		Establishment of an Interim     Governance (Governing     Governing Board (IGB) and     executive support secretariat     (SEC) to implement the validated     Strategic Action Plan      Terms of reference of Scientific     participation in the JIHR      Terms of reference of     Stakeholder participation in the     JIHR	<ul> <li>Mapping of national programmes.</li> <li>Identification of potential Scientific advisors and Invitation to join the IGB</li> </ul>	Identification and Selection of Stakeholders	INTERIM COORDINATING BODY FUNCTIONAL
2nd. semester 2015		First meeting of the IGB     (approval of board composition,     membership rules, agreement on     objectives, funding, evaluation,     communication, advocacy)	<ul> <li>Election of the Scientific Advisory Board (SAB)</li> <li>Strategic Research Agenda proposal</li> </ul>	Election of the     Stakeholder's Advisory     Board (SHAB)	



# 7. PRELIMINARY STRATEGIC ROADMAP OF THE EU-CELAC JOINT INITIATIVE ON HEALTH RESEARCH (2014-2020) - 2

2016	Strategic research agenda, terms		SHAB GB, SAB, SHAB, SECRETARI	AT.		
	of reference for a Pilot EU-CELAC					
	JIHR Action					
	JIHR support secretariat					
	established and operational.					
	Preparation of the sustainability					
	Plan, including financial support					
	for the secretariat.					
	Dissemination and advocacy of		FIRST EU-CELAC JIHR ACTIO	N		
	the JIHR		LAUNCHED			
2nd.	Approv. of the sustainability     15	t scientific operational   • Definition				
semester	Plan pi	an, including topics innovation	on facilitating SUSTAINABILITY PLAN			
2016	Negotiation of a second stage of form	or pilot initiative plan	DEFINED			
	the EU-CELAC JIHR					
	Pilot EU-CELAC JIHR action launched					
	<ul> <li>Renewal and extension of the partnership</li> </ul>	Renewal and extension of the partnership.				
	<ul> <li>Monitoring of EU-CELAC JIHR actions</li> </ul>	<ul> <li>Monitoring of EU-CELAC JIHR actions</li> <li>Definition of the Terms of Reference of the Assessment of the first stage of the EU-CELAC</li> </ul>				
	Definition of the Terms of Reference of the					
2017	JIHR.					
	Assessment of the first stage of the EU-CEI	Assessment of the first stage of the EU-CELAC JIHR.				
	_	1st EU-CELAC Health Research and Policy Forum (GB, SAB, SHAB, participants, stakeholders).				
	Launch of the Second Stage of EU-CELAC JI	stakenoraersj.				
	Evaluation of EU-CELAC JIHR actions					
	Use and dissemination of the research out					
	·		EVALUATION OF OUTCOMI	ES		
2010 2025	-	Evaluation of impact of the initiative				
2018-2020		2nd scientific operational plan     Undate of Street via Scientific Appendix				
		Update of Strategic Scientific Agenda     SU CSU AG Usaleh Bassasah and Balisus Farrare				
	EU-CELAC Health Research and Policy Foru					
	Assessment of the Governance and Action	rian performance and future progra	amming			



# **THANK YOU**




#### **EU-LAC Health Partners**







Dr. Rafael de Andrés (Coordinator)
ISCIII, Instituto de Salud Carlos III, Ministerio de
Economía y Competitividad, Spain



Dr. Stephanie Splett-Rudolph DLR, Deutsches Zentrum für Luft- und Raumfahrt e.V., Germany



Dr. Luis Tacsan Chen RIMAIS, Red Iberoamericana Ministerial de Aprendizaje e Investigación en Salud, Ministerio de Salud, Costa Rica



Dr. Paulo Buss FIOCRUZ, Fundação Oswaldo Cruz, Brazil



Dr. Joaquin Guinea
INNOVATEC, Sociedad para el Fomento de la
Innovación Tecnológica, Spain



Eng. Águeda Menvielle MINCYT, Ministerio de Ciencia, Tecnología Argentina e Innovación Productiva



Dr. Gabriela Montorzi COHRED, Council on Health Research for Development, Switzerland / Mexico



Dr. Diassina Di Maggio APRE, Agenzia per la Promozione della Ricerca, Italy



